Brief: XBiotech announces agreement with Cedars-Sinai Medical Center to evaluate MABP1 combination for the treatment of pancreatic cancer
20/09/2017 13:00
Sept 20 (Reuters) - Xbiotech Inc XBIT.O
* Xbiotech announces agreement with Cedars-Sinai Medical
Center to evaluate MABP1 in combination with Onivyde and
5-fluorouracil/folinic acid for the treatment of pancreatic
cancer
Source text for Eikon: ID:nGNXOEIYEa
Further company coverage: XBIT.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke